ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt
Release Date: July 11, 2023

ClinicalTrials.gov ID: NCT05502081

Study Identification

Unique Protocol ID:	MS.21.11.1737
Brief Title:	Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients
Official Title:	Clinical Study to Evaluate the Possible Efficacy and Safety of Antibodies Combination (Casirivimab and Imdevimab) Versus Standard Antiviral Therapy (Remdesivir and Favipravir) as Antiviral Agent Against Corona Virus 2 Infection in Hospitalized COVID-19 Patients
Secondary IDs:	35039/11/21 [Tanta University]

Study Status

Record Verification:	July 2023
Overall Status:	Completed
Study Start:	September 2, 2022 [Actual]
Primary Completion:	December 28, 2022 [Actual]
Study Completion:	December 28, 2022 [Actual]

Sponsor/Collaborators

Sponsor:	Mansoura University Hospital
Responsible Party:	Principal Investigator Investigator: Ahmed H Hassan, PharmD [ahhassan] Official Title: Principal Investigator Affiliation: Mansoura University Hospital
Collaborators:	

Oversight

U.S. FDA-regulated Drug:	Yes
U.S. FDA-regulated Device:	No
U.S. FDA IND/IDE:	Yes
IND/IDE Information:	FDA Center: CDER IND/IDE Number: 148069 Serial Number: Has Expanded Access: No
Human Subjects Review:	Board Status: Approved Approval Number: MS.21.11.1737 Board Name: Medical Research Ethics Committee Board Affiliation: Faculty of Medicine, Mansoura University Phone: +20502202773 Email: IRB.MFM@hotmail.com Address: Institutional Review Board(IRB) Office, Building A-Ground floor-Faculty of Medicine,Mansoura Unversity, Mansoura Egypt
Data Monitoring:	Yes
FDA Regulated Intervention:	Yes
Section 801 Clinical Trial:	Yes

Study Description

Brief Summary: Introduction:

Corona Virus induced disease – 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of 2021 year, various advances in pharmacotherapy against COVID-19 have emerged.

Regarding antiviral therapy, Casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Standard antiviral therapy against COVID-19 includes Remdesivir and Favipravir.

Aim of Study:

1. To compare the efficacy of antibodies cocktail (casirivimab and imdevimab), Remdesivir and Favipravir in reducing 28-day mortality in hospitalized patients with moderate, severe or critical COVID19
2. To compare safety of antibodies cocktail (casirivimab and imdevimab), Remdesivir and Favipravir by monitoring hypersensitivity and infusion related reactions or other significant adverse effects

Patients and Population:

265 COVID-19 Polymerase Chain Reaction (PCR) confirmed patients with indication for antiviral therapy is included in this study and will be divided into 3 groups (1:2:2):

1. Group A: REGN3048-3051(Antibodies cocktail (casirivimab and imdevimab))
2. group B: Remdesivir
3. group C: Favipravir

Methods:

Study design is single blind non-Randomized Controlled Trial (non-RCT). The drugs of the study are owned by Mansoura University Hospital (MUH), and prescribed by chest diseases lectures of faculty of medicine-Mansoura University. The duration of study is about 6 months after ethical approval.

Detailed Description: I. INTRODUCTION

1.1. COVID-19 overview and classification

COVID-19 is an infectious viral disease caused by sever acute respiratory syndrome-corona virus 2 (SARS CoV-2) that has affected large number of people all over the world with high mortality rate. COVID-19 infection has been classified as:

1. Mild Illness: Individuals who have any of the various signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) but who do not have shortness of breath, dyspnea, or abnormal chest imaging.
2. Moderate Illness: Individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have an oxygen saturation (SpO2) ≥94% on room air at sea level.
3. Severe Illness: Individuals who have Saturation pressure of oxygen (SpO2) <94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mm Hg, respiratory frequency >30 breaths/min, or lung infiltrates >50%.
4. Critical Illness: Individuals who have respiratory failure, septic shock, and/or multiple organ dysfunctions.

Covid-19 pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of 2021 year, various advances in pharmacotherapy against COVID-19 have emerged.

1.2. Standard and controversial antivirals used in treatment of COVID-19 (Remdesivir and Favipravir)

Regarding antiviral drugs used in treatment of COVID-19, Remdesivir is a standard antiviral against COVID-19 and has been approved by Food and drug administration (FDA) for treatment of mild, moderate, sever and critical hospitalized COVID-19 patients. Other drugs have shown controversial antiviral activity include: favipravir, ivermectin, nitazoxanide, hydroxychloroquine, ribavirin. Favipravir became a standard antiviral which has been used for treatment of mild and moderate COVID-19 outpatients.

1.3. Advances in immunotherapy for treatment of COVID-19

Recently with the end of 2020, immunotherapy to target virus antigen has developed. Figure 1 shows two types of immunotherapy include active and passive immunotherapy. Active immunotherapy is to enhance body to produce antibodies against virus as by vaccination. Passive immunotherapy involves direct administration of prepared antibodies acting specifically against virus or administration of product containing antibodies like plasma.

There are three targets for these antibodies to work as antiviral including:

1. antibodies that prevent the virus attachment and entry
2. antibodies that inhibit the virus replication and transcription

3. antibodies that hinder various steps of the immune system response Table 1 includes various types of antibodies under investigation for treatment of COVID-19 and their targets.

1.4. Casirivimab and Imdevimab as antibodies cocktail against COVID-19

In the present study, the point of research is antibodies cocktail including REGN3048-3051(casirivimab and imdevimab).REGN3048 and REGN3051 are human monoclonal antibodies targeting the spike glycoprotein on surface of viral particles thereby preventing viral entry into human cells through the angiotensin-converting enzyme 2(ACE2) receptor, and have shown promising antiviral activity and need for further investigation to prove their benefit in COVID patients.

Previous study on REGN3048-3051 has mentioned that both efficacy and safety of this antibodies cocktail are proved in COVID-19 outpatients treatment in both low (2.4 g of REGN-COV2), or high (8.0 g of REGN-COV2) dose when compared to placebo, Efficacy is measured as

1. Virologic Efficacy Time-weighted average change from baseline in viral load through day 7 (log10 scale) in patient.
2. Clinical Efficacy Percentage of patients with one or more medically attended visits and Symptoms offset at day 7

Safety is measured as Percentage of treated patients who experience infusion related and hypersensitivity reactions and incidence of any serious and unexpected adverse effect.

This previous study concluded that efficacy is greater and more obvious in seronegative outpatients (whose immune response is not developed yet to produce antibodies against virus) and with high baseline viral load outpatients.

Now, data is available for these new antibodies cocktails. The U.S. FDA has allowed an Emergency Use Authorization (EUA) for casirivimab and imdevimab combination in the treatment and post-exposure prophylaxis of mild and moderate COVID-19 in adults and pediatric outpatients (more than12 years of age and not less than 40 kg) with positive PCR results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19 requiring hospitalization or causing death..

In contrast, REGN3048 and REGN3051 are still not authorized for use in patients:

- who are hospitalized due to COVID-19, OR
- who require oxygen therapy due to COVID-19, OR
- who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity(FDA, 2021).

Now, casirivimab and imdevimab are approved investigational antibodies, Serious and unexpected adverse effects can occur that not previously reported with their use.

Confirmed adverse effects include hypersensitivity and infusion related reactions and the study have showed that there is no difference in safety profile between intravenous (I.V) infusion and subcutaneous (S.C) injection. Data about use during pregnancy and breastfeeding mother is insufficient yet. Also, Data not support any dosage adjustment in hepatic and renal patients.

This antibody combination follows linear pharmacokinetics after its single intravenous doses with half-life of about 25 to 37 days for both antibodies. Regarding elimination, this combination is not metabolized by liver cytochrome enzymes ,and not excreted by kidneys.

Limitations of the previous study performed on antibody cocktail include:

1. short duration of follow up

2. not used much clinical relevant outcomes like mortality rate
3. Not studied the long term effect of antiviral efficacy in lowering viral load on inflammatory markers.
4. Study performed on non-hospitalized patients only and not included hospitalized patients (trial is done only on outpatients and not inpatients)

II. AIM OF THE STUDY:

1. To evaluate the efficacy of antibodies cocktail (casirivimab and imdevimab) compared to standard antiviral therapy in reducing 28-day mortality in hospitalized patients with moderate, severe or critical COVID19
2. To evaluate safety of antibodies cocktail (casirivimab and imdevimab) compared to standard antiviral therapy by monitoring of hypersensitivity and infusion related reactions or other significant adverse effects

III. PATIENTS AND POPULATION

265 COVID-19 PCR confirmed patients with indication for antiviral therapy is included in this study and will be randomized (2:1:1) into 3 groups

1. Group A: REGN3048-3051(Antibodies cocktail (casirivimab and imdevimab))
2. group B: Remdesivir
3. group C: Favipravir

Population in this study are patients hospitalized in isolation hospital-Mansoura university.

A computer file containing a written informed consent from included patients will be provided. Paper will not be a tool for providing agreement by patients or their relatives to avoid transmission of infection.

IV. INTERVENTIONS

Population included in this study will be assigned into 3 groups with 1:2:2 ratios to receive either antibodies cocktail or standard antiviral therapy (remdesvir, favipravir).

Group A patients will receive REGN3048-3051(Antibodies cocktail (casirivimab and imdevimab)) in low-dose regimen 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes.

Group B patients will receive Remdesivir :

Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes

Group C patients will receive Favipravir :

Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours

Patients will be received standard of care by Physicians, Clinical pharmacist , Nurses and as guided by Egyptian COVID-19 treatment protocol.

V. METHOD

The type of this study is single blind non-RCT and is considered a Phase IV Clinical trial (post-marketing study) to report efficacy and safety of new medicine.

We use PubMed search tool to find clinical studies that performed to test efficacy and safety of developed immunotherapy in treatment of COVID-19 with about 4,000 results with focusing on antibodies developed as antiviral against COVID-19 obtaining only 70 results from which REGN-COV2, a Neutralizing Antibody Cocktail is selected with its only one clinical study up to now (REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19) which is published in New England Journal of Medicine on January 21, 2021.

Another resource used to obtain data is Fact Sheet for Health Care Providers- EUA OF casirivimab and imdevimab which provides clinical data about the use of this antibodies cocktail. Endnote citation software is used for citation of references.

Conditions

Conditions: COVID-19

Keywords: COVID-19
Casirivimab & Imdevimab
Remdesivir
Favipravir

Study Design

Study Type: Interventional

Primary Purpose: Treatment

Study Phase: Phase 4

Interventional Study Model: Parallel Assignment

Number of Arms: 3

Masking: Single (Participant)

Allocation: Non-Randomized

Enrollment: 265 [Actual]

Arms and Interventions

Arms	Assigned Interventions
Experimental: casirivimab and imdevimab casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes.	Drug: Casirivimab and Imdevimab Drug Combination antiviral Monoclonal Antibodies Other Names: • REGN-COV2
Experimental: Remdesivir	Drug: Remdesivir antiviral drug

Arms	Assigned Interventions
Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes	Other Names: • Veklury
Experimental: Favipravir Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours	Drug: Favipiravir antiviral drug Other Names: • Avigan

Outcome Measures

[See Results Section.]

Eligibility

Minimum Age: 12 Years

Maximum Age:

Sex: All

Gender Based: No

Accepts Healthy Volunteers: Yes

Criteria: Inclusion Criteria:

1. age more than 12 years old.
2. weight not less than 40 kg.
3. Moderate, sever or critical COVID-19 disease as defined by WHO.
4. PCR- confirmed patients to be Positive before inclusion.

Exclusion Criteria:

1. history of hypersensitivity or infusion related reactions after administration of monoclonal antibodies.
2. prior use of standard antiviral therapy (remedsvir or favipravir).
3. Current use of controversial antiviral therapy (hydroxychloroquine, ivermectin, nitazoxanide, oseltemavir, acyclovir, ribavirine, lopinvir/rotinvir, sofosfbuvir, decltasevir, semipirvir, azithromycin).
4. patients expected to die within 48 hours.

Contacts/Locations

Central Contact Person: Ahmed H Hassan, Dr
Telephone: 2001554658010

Email: ahmedony26@gmail.com

Central Contact Backup: Smar T Radwan, Prof

Study Officials: Shar K Hegazy, prof
Study Director
Tanta Unversity

Locations: **Egypt**
El-gomhoria St
Mansoura, El-dkhalia, Egypt, 050
Contact: Ahmed H Hassan, Dr 2001554658010 ahmedony26@gmail.com
Contact: Smar T Radwan, Prof
Sub-Investigator: Shar K Hegazy, Prof

IPDSharing

Plan to Share IPD: Yes
After the end and publication of the study

Supporting Information:
Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)

Time Frame:
After the end and publication of the study

Access Criteria:
all will be accessiable

URL:

References

Citations: Okonji EF, Okonji OC, Mukumbang FC, Van Wyk B. Understanding varying COVID-19 mortality rates reported in Africa compared to Europe, Americas and Asia. Trop Med Int Health. 2021 Jul;26(7):716-719. doi: 10.1111/tmi.13575. Epub 2021 May 1. PubMed 33733568

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [updated September 29, 2021. Available from: https://www.covid19treatmentguidelines.nih.gov.

Umakanthan S, Chattu VK, Ranade AV, Das D, Basavarajegowda A, Bukelo M. A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19. AIMS Public Health. 2021 Feb 1;8(1):137-153. doi: 10.3934/publichealth.2021011. eCollection 2021. PubMed 33575413

Aleem A, Kothadia JP. Remdesivir. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.; 2021

de Almeida SMV, Santos Soares JC, Dos Santos KL, Alves JEF, Ribeiro AG, Jacob ITT, da Silva Ferreira CJ, Dos Santos JC, de Oliveira JF, de Carvalho Junior LB, de Lima MDCA. COVID-19 therapy: What weapons do we bring into battle? Bioorg Med Chem. 2020 Dec 1;28(23):115757. doi: 10.1016/j.bmc.2020.115757. Epub 2020 Sep 10. PubMed 32992245

Owji H, Negahdaripour M, Hajighahramani N. Immunotherapeutic approaches to curtail COVID-19. Int Immunopharmacol. 2020 Nov;88:106924. doi: 10.1016/j.intimp.2020.106924. Epub 2020 Aug 21. PubMed 32877828

Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, Giordano S, Lanza K, Negron N, Ni M, Wei Y, Atwal GS, Murphy AJ, Stahl N, Yancopoulos GD, Kyratsous CA. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020 Aug 21;369(6506):1014-1018. doi: 10.1126/science.abd0831. Epub 2020 Jun 15. PubMed 32540904

Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, Fulton BO, Yan Y, Koon K, Patel K, Chung KM, Hermann A, Ullman E, Cruz J, Rafique A, Huang T, Fairhurst J, Libertiny C, Malbec M, Lee WY, Welsh R, Farr G, Pennington S, Deshpande D, Cheng J, Watty A, Bouffard P, Babb R, Levenkova N, Chen C, Zhang B, Romero Hernandez A, Saotome K, Zhou Y, Franklin M, Sivapalasingam S, Lye DC, Weston S, Logue J, Haupt R, Frieman M, Chen G, Olson W, Murphy AJ, Stahl N, Yancopoulos GD, Kyratsous CA. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020 Aug 21;369(6506):1010-1014. doi: 10.1126/science.abd0827. Epub 2020 Jun 15. PubMed 32540901

Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, Perry C, Pan C, Hosain R, Mahmood A, Davis JD, Turner KC, Hooper AT, Hamilton JD, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Kohli A, Sachdeva Y, Graber X, Kowal B, DiCioccio T, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD; Trial Investigators. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17. PubMed 33332778

FDA. EMERGENCY USE AUTHORIZATION (EUA) OF REGEN-COV (casirivimab and imdevimab): Food and Drug Adminsteration (FDA); 2021 [updated 16/9/2021. first:[FACT SHEET FOR HEALTH CARE PROVIDERS,]. Available from: https://www.fda.gov/media/145611/download

WHO COVID19 disease progression ordinal scale. February 18, 2020. [Available from: https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf

Placais L, Richier Q, Noel N, Lacombe K, Mariette X, Hermine O. Immune interventions in COVID-19: a matter of time? Mucosal Immunol. 2022 Feb;15(2):198-210. doi: 10.1038/s41385-021-00464-w. Epub 2021 Oct 28. PubMed 34711920

Yang Z, Hu Q, Huang F, Xiong S, Sun Y. The prognostic value of the SOFA score in patients with COVID-19: A retrospective, observational study. Medicine (Baltimore). 2021 Aug 13;100(32):e26900. doi: 10.1097/MD.0000000000026900. PubMed 34397917

Links:	
Available IPD/Information:	

Documents

Study Protocol, Statistical Analysis Plan and Informed Consent Form
Document Date: January 24, 2023
Uploaded: 01/24/2023 15:13

Study Results

Participant Flow

Recruitment Details	from 1/11/2021 to 29/5/2022 at isolation hospital, Mansoura university
Pre-assignment Details	assignment is applied after admission of participants

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Overall Study

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Started	53	106	106

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Completed	53	106	106
Not Completed	0	0	0

Baseline Characteristics

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Baseline Measures

		Casirivimab and Imdevimab	Remdesivir	Favipravir	Total
Overall Number of Participants		53	106	106	265
Age, Continuous Mean (Standard Deviation) Unit of measure: years	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		58.34 (16.096)	59.3 (15.98)	65.02 (14.26)	60.88 (15.44)
Sex: Female, Male Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	Female	24 45.28%	42 39.62%	61 57.55%	127 47.92%
	Male	29 54.72%	64 60.38%	45 42.45%	138 52.08%

		Casirivimab and Imdevimab	Remdesivir	Favipravir	Total
Race/Ethnicity, Customized Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
Middle eastern		53 100%	106 100%	106 100%	265 100%
Number of co-morbidities Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	0	10 18.87%	32 30.19%	22 20.75%	64 24.15%
	1	16 30.19%	27 25.47%	19 17.92%	62 23.4%
	2	14 26.42%	28 26.42%	33 31.13%	75 28.3%
	3	11 20.75%	16 15.09%	18 16.98%	45 16.98%
	4	2 3.77%	2 1.89%	10 9.43%	14 5.28%
	5	0 0%	1 0.94%	3 2.83%	4 1.51%
	6	0 0%	0 0%	1 0.94%	1 0.38%
Method of diagnosis Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	symptoms	0 0%	0 0%	0 0%	0 0%
	laboratory and radiology	0 0%	0 0%	0 0%	0 0%
	polymerase chain reaction confirmed	53 100%	106 100%	106 100%	265 100%
Severity of COVID-19 Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	moderate	18 33.96%	20 18.87%	20 18.87%	58 21.89%
	severe	27 50.94%	60 56.6%	53 50%	140 52.83%

		Casirivimab and Imdevimab	Remdesivir	Favipravir	Total
	critical	8 15.09%	26 24.53%	33 31.13%	67 25.28%
World health organization clinical progression scale [1] Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	3	0 0%	1 0.94%	0 0%	1 0.38%
	4	15 28.3%	5 4.72%	10 9.43%	30 11.32%
	5	35 66.04%	100 94.34%	96 90.57%	231 87.17%
	6	3 5.66%	0 0%	0 0%	3 1.13%

[1] Measure Description: 0. Uninfected

Ambulatory mild disease

1. Asymptomatic; viral RNA detected
2. Symptomatic; independent.
3. Symptomatic; assistance needed

Hospitalized: moderate disease

4. Hospitalized; no oxygen therapy
5. Hospitalized; oxygen by mask or nasal prongs

Hospitalized: sever disease

6. Hospitalized; oxygen by NIV or high flow
7. Intubation and mechanical ventilation, pO2 /FIO2 ≥ 150 or Spo2 /FiO2 ≥200
8. Mechanical ventilation pO2/FiO2 <150 (SpO2 /FiO2 < 200) or vasopressors
9. Mechanical ventilation pO2 / FiO2 < 150 and vasopressors, dialysis or ECMO

Dead

10. Dead

Number of symptoms Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	2	4 7.55%	2 1.89%	2 1.89%	8 3.02%
	3	13 24.53%	6 5.66%	4 3.77%	23 8.68%
	4	32 60.38%	97 91.51%	97 91.51%	226 85.28%
	5	4 7.55%	1 0.94%	3 2.83%	8 3.02%

		Casirivimab and Imdevimab	Remdesivir	Favipravir	Total
Antibiotics use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	53 100%	106 100%	106 100%	265 100%
	no	0 0%	0 0%	0 0%	0 0%
macrolide use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	8 15.09%	8 7.55%	2 1.89%	18 6.79%
	no	45 84.91%	98 92.45%	104 98.11%	247 93.21%
fluoroquinolone use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	41 77.36%	92 86.79%	95 89.62%	228 86.04%
	no	12 22.64%	14 13.21%	11 10.38%	37 13.96%
cephalosporin use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	39 73.58%	86 81.13%	83 78.3%	208 78.49%
	no	14 26.42%	20 18.87%	23 21.7%	57 21.51%
carbapenem use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	10 18.87%	32 30.19%	22 20.75%	64 24.15%
	no	43 81.13%	74 69.81%	84 79.25%	201 75.85%
piperacillin use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	0 0%	0 0%	0 0%	0 0%
	no	53 100%	106 100%	106 100%	265 100%

		Casirivimab and Imdevimab	Remdesivir	Favipravir	Total
amoxicillin/ clavulanate use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
yes		0 0%	0 0%	0 0%	0 0%
no		53 100%	106 100%	106 100%	265 100%
co-trimoxazole use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	0 0%	0 0%	0 0%	0 0%
	no	53 100%	106 100%	106 100%	265 100%
linezolide use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	5 9.43%	12 11.32%	4 3.77%	21 7.92%
	no	48 90.57%	94 88.68%	102 96.23%	244 92.08%
teicoplanin use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	1 1.89%	0 0%	2 1.89%	3 1.13%
	no	52 98.11%	106 100%	104 98.11%	262 98.87%
Anticoagulant use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	49 92.45%	101 95.28%	96 90.57%	246 92.83%
	no	4 7.55%	5 4.72%	10 9.43%	19 7.17%
dose of anticoagulant Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	prophylactic	39 73.58%	80 75.47%	81 76.42%	200 75.47%
	therapeutic	14 26.42%	26 24.53%	25 23.58%	65 24.53%

		Casirivimab and Imdevimab	Remdesivir	Favipravir	Total
Antiplatelet use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	5 9.43%	6 5.66%	0 0%	11 4.15%
	no	48 90.57%	100 94.34%	106 100%	254 95.85%
Steriods use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	45 84.91%	105 99.06%	98 92.45%	248 93.58%
	no	8 15.09%	1 0.94%	8 7.55%	17 6.42%
Additive therapy use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	51 96.23%	106 100%	105 99.06%	262 98.87%
	no	2 3.77%	0 0%	1 0.94%	3 1.13%
paracetamol use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	50 94.34%	105 99.06%	106 100%	261 98.49%
	no	3 5.66%	1 0.94%	0 0%	4 1.51%
zinc use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	4 7.55%	0 0%	1 0.94%	5 1.89%
	no	49 92.45%	106 100%	105 99.06%	260 98.11%
acetylcysteine use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	52 98.11%	106 100%	106 100%	264 99.62%
	no	1 1.89%	0 0%	0 0%	1 0.38%

		Casirivimab and Imdevimab	Remdesivir	Favipravir	Total
lactoferrin use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	1 1.89%	0 0%	0 0%	1 0.38%
	no	52 98.11%	106 100%	106 100%	264 99.62%
vitamin C use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	4 7.55%	7 6.6%	1 0.94%	12 4.53%
	no	49 92.45%	99 93.4%	105 99.06%	253 95.47%
Oxygen therapy use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	37 69.81%	99 93.4%	102 96.23%	238 89.81%
	no	16 30.19%	7 6.6%	4 3.77%	27 10.19%
Nasal Prongs use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	18 33.96%	35 33.02%	39 36.79%	92 34.72%
	no	35 66.04%	71 66.98%	67 63.21%	173 65.28%
Simple Face Mask use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	30 56.6%	82 77.36%	87 82.08%	199 75.09%
	no	23 43.4%	24 22.64%	19 17.92%	66 24.91%
Mask Reservoir use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	8 15.09%	33 31.13%	14 13.21%	55 20.75%

		Casirivimab and Imdevimab	Remdesivir	Favipravir	Total
	no	45 84.91%	73 68.87%	92 86.79%	210 79.25%
High Flow Nasal Cannula use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	5 9.43%	22 20.75%	18 16.98%	45 16.98%
	no	48 90.57%	84 79.25%	88 83.02%	220 83.02%
Continuous Positive Attenuated Pressure use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	4 7.55%	39 36.79%	36 33.96%	79 29.81%
	no	49 92.45%	67 63.21%	70 66.04%	186 70.19%
Invasive Mechanical Ventilation use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	1 1.89%	29 27.36%	29 27.36%	59 22.26%
	no	52 98.11%	77 72.64%	77 72.64%	206 77.74%
Vasopressor use Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	0 0%	23 21.7%	18 16.98%	41 15.47%
	no	53 100%	83 78.3%	88 83.02%	224 84.53%
Prone Positioning Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	yes	0 0%	5 4.72%	9 8.49%	14 5.28%
	no	53 100%	101 95.28%	97 91.51%	251 94.72%

		Casirivimab and Imdevimab	Remdesivir	Favipravir	Total
Heart rate Mean (Standard Deviation) Unit of measure: beats/ minute	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		82.40 (12.443)	85.7 (16.072)	87.02 (16.79)	85.04 (15.1)
Respiratory rate Mean (Standard Deviation) Unit of measure: breaths/ minute	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		24.25 (3.246)	25.4 (5.58)	24.72 (5.012)	24.79 (4.612)
Body temperature Mean (Standard Deviation) Unit of measure: degree Celsius	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		36.951 (0.492)	36.938 (0.456)	36.906 (1.18)	36.92 (0.709)
O2 saturation on Oxygen therapy Mean (Standard Deviation) Unit of measure: percentage of O2 saturation	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		96.26 (2.391)	95.86 (3.795)	96.01 (3.130)	96.04 (3.105)
O2 saturation on Room air Mean (Standard Deviation) Unit of measure: percentage of O2 saturation	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		92.36 (4.816)	87.62 (7.171)	88.35 (7.006)	89.44 (6.33)
Aspartate aminotransferase level Mean (Standard Deviation) Unit of measure: Units/liter	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		45.62 (38.619)	52.95 (35.49)	54.52 (67.85)	51.03 (47.319)

		Casirivimab and Imdevimab	Remdesivir	Favipravir	Total
Alanine aminotransferase level Mean (Standard Deviation) Unit of measure: Units/liter	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		33.34 (27.166)	33.27 (22.826)	42.79 (77.37)	36.46 (42.454)
Bilirubin level Mean (Standard Deviation) Unit of measure: milligram/ deciliter	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		0.5472 (0.299)	0.6228 (0.79)	0.7327 (0.69)	0.634 (0.593)
Albumin level Mean (Standard Deviation) Unit of measure: gram/ deciliter	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		3.1774 (0.461)	3.1715 (0.48)	3.1021 (0.512)	3.15 (0.484)
Prothrombin Time [1] Mean (Standard Deviation) Unit of measure: seconds	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		14.575 (1.68)	15.338 (1.997)	15.69 (2.476)	15.201 (2.051)
		[1] Measure Description: the time it takes for the liquid portion (plasma) of your blood to clot.			
International normalized ratio [1] Mean (Standard Deviation) Unit of measure: Ratio	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		1.2625 (0.201)	1.3436 (0.239)	1.3868 (0.296)	1.33 (0.245)
		[1] Measure Description: a ratio of the patient's PT to a control PT standardized for the potency of the thromboplastin reagent developed by the World Health Organization (WHO) using the following formula: INR = Patient PT/ Control PT. normal value is 1 higher value means higher tendency for bleeding lower value means higher tendency for clotting			

		Casirivimab and Imdevimab	Remdesivir	Favipravir	Total
Serum creatinine Mean (Standard Deviation) Unit of measure: milligram/ deciliter	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		1.2092 (1.355)	1.0999 (0.924)	1.8807 (1.912)	1.3966 (1.397)
Total leukocytic count Mean (Standard Deviation) Unit of measure: 10^3 cells/ mm^3	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		8.6934 (4.129)	8.4562 (5.044)	11.0268 (9.4)	9.39 (6.191)
Lymphocyte count Mean (Standard Deviation) Unit of measure: 10^9 cells/L	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		0.9658 (0.521)	0.9123 (0.429)	1.4834 (5.62)	1.12 (2.19)
Hemoglobin level Mean (Standard Deviation) Unit of measure: gram/ deciliter	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		12.59 (1.58)	12.44 (2.07)	11.94 (2.54)	12.32 (2.063)
Hematocrit level Mean (Standard Deviation) Unit of measure: percentage of total blood volume	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		39.317 (6.045)	36.975 (5.586)	35.259 (8.559)	37.18 (6.73)
Platelet count Mean (Standard Deviation) Unit of measure: 10^3 cells/ uL	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		234.913 (91.5)	211.613 (92.3)	217.591 (122)	221.37 (101.93)

		Casirivimab and Imdevimab	Remdesivir	Favipravir	Total
Lactate dehydrogenase level Mean (Standard Deviation) Unit of measure: international units per liter	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		413.06 (294.7)	389.81 (222.668)	378.5 (250.183)	393.79 (255.85)
Creatine kinase level Mean (Standard Deviation) Unit of measure: Units/liter	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		185.96 (207.6)	228.07 (367.1)	232.75 (287)	215.59 (287.23)
D-dimer level Mean (Standard Deviation) Unit of measure: µg/mL	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		0.6189 (0.493)	0.1433 (0.227)	0.2915 (0.385)	0.351 (0.368)
C-reactive protein level Mean (Standard Deviation) Unit of measure: milligram/ liter	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		61.566 (39.71)	61.292 (35.3)	95.513 (157.8)	72.79 (77.60)
Ferritin level Mean (Standard Deviation) Unit of measure: micrograms per liter	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		442.34 (190.4)	418.06 (193.8)	1158.4 (6953)	672.93 (2445.73)
Sodium level Mean (Standard Deviation) Unit of measure: millimole/ liter	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		146.472 (30.7)	145.243 (20)	144.315 (18.5)	145.34 (23.06)

		Casirivimab and Imdevimab	Remdesivir	Favipravir	Total
Potassium level Mean (Standard Deviation) Unit of measure: millimole/ liter	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		3.6228 (0.514)	3.47 (0.674)	3.79 (0.829)	3.627 (0.672)
arterial oxygen pressure Mean (Standard Deviation) Unit of measure: millimeters of mercury	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		36.689 (12.59)	37.325 (14.6)	37.603 (12.08)	37.205 (13.09)
ratio of arterial Oxygen pressure to fraction inspired of Oxygen [1] Mean (Standard Deviation) Unit of measure: Ratio	Number Analyzed	53 participants	106 participants	106 participants	265 participants
		223.5057 (207)	156.7358 (171)	164.142 (138)	181.46 (516)
		[1] Measure Description: PaO2/FiO2 ratio is the ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2 expressed as a fraction, not a percentage) also known as the Horowitz index, the Carrico index, and (most conveniently) the P/F ratio. The PaO2/FiO2 ratio is frequently used to determine the severity of lung injury in mechanically ventilated patients. normal >300 mild ARDS(acute respiratory distress syndrome)= 200-300 moderate ARDS= 100-200 severe ARDS <100			
Glasgow coma score [1] Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	4	0 0%	2 1.89%	0 0%	2 0.75%
	6	0 0%	1 0.94%	0 0%	1 0.38%
	8	0 0%	0 0%	1 0.94%	1 0.38%
	9	0 0%	0 0%	1 0.94%	1 0.38%
	10	0 0%	2 1.89%	8 7.55%	10 3.77%
	13	0 0%	0 0%	3 2.83%	3 1.13%
	14	1 1.89%	4 3.77%	7 6.6%	12 4.53%

		Casirivimab and Imdevimab	Remdesivir	Favipravir	Total
	15	52 98.11%	97 91.51%	86 81.13%	235 88.68%
		[1] Measure Description: minimum 0 means dead maximum 15 means fully conscious higher score means better consciousness Eye opening response spontaneous 4 To verbal command 3 To pain 2 None 1 Verbal response Oriented conversation 5 Disoriented conversation 4 Inappropriate words Incomprehensible words 3 Incomprehensible sound 2 None 1 Motor response Obeys verbal command 6 Localized painful stimuli 5 Flexion withdrawal from painful stimuli 4 Decorticate response to painful stimuli 3 None 1			
Sequential organ function assessment [1] Measure Type: Count of Participants Unit of measure: participants	Number Analyzed	53 participants	106 participants	106 participants	265 participants
	0	11 20.75%	2 1.89%	1 0.94%	14 5.28%
	1	1 1.89%	1 0.94%	4 3.77%	6 2.26%
	2	3 5.66%	9 8.49%	3 2.83%	15 5.66%
	3	12 22.64%	25 23.58%	17 16.04%	54 20.38%
	4	17 32.08%	36 33.96%	28 26.42%	81 30.57%
	5	7 13.21%	18 16.98%	17 16.04%	42 15.85%
	6	0 0%	6 5.66%	13 12.26%	19 7.17%
	7	2 3.77%	4 3.77%	9 8.49%	15 5.66%
	8	0 0%	3 2.83%	7 6.6%	10 3.77%
	9	0 0%	1 0.94%	3 2.83%	4 1.51%
	10	0 0%	1 0.94%	3 2.83%	4 1.51%
	14	0 0%	0 0%	1 0.94%	1 0.38%
		[1] Measure Description: minimum 0 maximum 24 higher score means worse case PaO2/FiO2 0(> 400) 1(≤ 400) 2(≤ 300) 3(≤ 200 with respiratory support) 4(≤ 100 with respiratory support),Platelets 0 >150 1 101-150 2 51-100 3 21-50 4 ≤20, bilirubin 0 <1.2 mg/dl1 1.2-1.9 mg/dl 2 2-5.9 mg/dl 3 6-11.9 mg/dl 4 >12 mg/dl, Blood Pressure 0 no Hypotension 1MAP< 70 mmHg2 On dopamine≤ 5 mcg/Kg/min 3 On dopamine > 5 mcg/ kg/ min , 4 On dopamine >15 mcg/ kg/ min or epinephrine >0.1,GCS0 (15)1(13-14)2(10-12) 3(6-9) 4(<6), Renal function Creatinine 0 < 1.2 1 1.2-1.92 2-3.4 3 3.5-4.9 4 >5			

Outcome Measures

1. Primary Outcome Measure:

Measure Title	28-days Mortality Rate
Measure Description	Dead or alive
Time Frame	28 days

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		53	106	106
28-days Mortality Rate Measure Type: Count of Participants Unit of measure: participants	dead	1 1.89%	34 32.08%	43 40.57%
	alive	52 98.11%	72 67.92%	63 59.43%

Statistical Analysis 1 for 28-days Mortality Rate

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for 28-days Mortality Rate

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.176
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for 28-days Mortality Rate

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for 28-days Mortality Rate

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

2. Primary Outcome Measure:

Measure Title	Number of Participants With Positive or Negative Polymerase Chain Reaction (PCR) Test Results at End of Hospital Visit
Measure Description	positive or negative
Time Frame	up to 60 days

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		53	106	106
Number of Participants With Positive or Negative Polymerase Chain Reaction (PCR) Test Results at End of Hospital Visit Measure Type: Count of Participants Unit of measure: participants	positive	36 67.92%	92 86.79%	78 73.58%
	negative	17 32.08%	14 13.21%	28 26.42%

Statistical Analysis 1 for Number of Participants With Positive or Negative Polymerase Chain Reaction (PCR) Test Results at End of Hospital Visit

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]
Statistical Test of Hypothesis	P-Value	0.011
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Number of Participants With Positive or Negative Polymerase Chain Reaction (PCR) Test Results at End of Hospital Visit

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]
Statistical Test of Hypothesis	P-Value	0.021
	Comments	[Not specified]
	Method	Kruskal-Wallis

	Comments	[Not specified]

Statistical Analysis 3 for Number of Participants With Positive or Negative Polymerase Chain Reaction (PCR) Test Results at End of Hospital Visit

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.42
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Number of Participants With Positive or Negative Polymerase Chain Reaction (PCR) Test Results at End of Hospital Visit

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.007
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

3. Primary Outcome Measure:

Measure Title	Number of Participants With Infusion Related Reactions, Hypersensitivity Reactions and Any Serious Adverse Events
Measure Description	yes or no
Time Frame	up to 60 days

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		53	106	106
Number of Participants With Infusion Related Reactions, Hypersensitivity Reactions and Any Serious Adverse Events Measure Type: Count of Participants Unit of measure: participants	yes	0 0%	0 0%	0 0%
	no	53 100%	106 100%	106 100%

Statistical Analysis 1 for Number of Participants With Infusion Related Reactions, Hypersensitivity Reactions and Any Serious Adverse Events

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.99
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

4. Secondary Outcome Measure:

Measure Title	Need for Invasive Mechanical Ventilation
Measure Description	yes or no
Time Frame	up to 60 days

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		53	106	106
Need for Invasive Mechanical Ventilation	yes	1 1.89%	22 20.75%	22 20.75%
	no	52 98.11%	84 79.25%	84 79.25%

			Casirivimab and Imdevimab	Remdesivir	Favipravir
Measure Type:	Count of Participants				
Unit of measure:	participants				

Statistical Analysis 1 for Need for Invasive Mechanical Ventilation

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.005
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Need for Invasive Mechanical Ventilation

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.99
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Need for Invasive Mechanical Ventilation

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.003
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Need for Invasive Mechanical Ventilation

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.003
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

5. Secondary Outcome Measure:

Measure Title	Oxygen Support Duration (Days)
Measure Description	in days
Time Frame	up to 60 days

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug

	Description
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	53	106	106
Oxygen Support Duration (Days) Mean (Standard Deviation) Unit of measure: days	3.72 (3.527)	9.2 (7.107)	7.46 (5.077)

Statistical Analysis 1 for Oxygen Support Duration (Days)

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Oxygen Support Duration (Days)

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.119
	Comments	[Not specified]

	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Oxygen Support Duration (Days)

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Oxygen Support Duration (Days)

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

6. Secondary Outcome Measure:

Measure Title	Time to Clinical Improvement (Defined as 2 Points Reduction in the WHO Disease Ordinal Progression Scale or Discharge, Whatever Happens First

Measure Description	in days WHO disease ordinal progression scale 0= Uninfected Ambulatory mild disease 1. Asymptomatic; viral RNA detected 2. Symptomatic; independent. 3. Symptomatic; assistance needed Hospitalized: moderate disease 4. Hospitalized; no oxygen therapy 5. Hospitalized; oxygen by mask or nasal prongs Hospitalized: sever disease 6. Hospitalized; oxygen by NIV or high flow 7. Intubation and mechanical ventilation, pO2 /FIO2 ≥ 150 or Spo2 /FiO2 ≥200 8. Mechanical ventilation pO2/FiO2 <150 (SpO2 /FiO2 < 200) or vasopressors 9. Mechanical ventilation pO2 / FiO2 < 150 and vasopressors, dialysis or ECMO Dead 10. Dead
Time Frame	up to 60 days

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	53	106	106

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Time to Clinical Improvement (Defined as 2 Points Reduction in the WHO Disease Ordinal Progression Scale or Discharge, Whatever Happens First Mean (Standard Deviation) Unit of measure: days	7.4 (3.101)	8.33 (6.38)	7.75 (4.265)

Statistical Analysis 1 for Time to Clinical Improvement (Defined as 2 Points Reduction in the WHO Disease Ordinal Progression Scale or Discharge, Whatever Happens First

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.933
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

7. Secondary Outcome Measure:

Measure Title	Duration of Hospitalization
Measure Description	in days
Time Frame	up to 60 days

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies

	Description
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	53	106	106
Duration of Hospitalization Mean (Standard Deviation) Unit of measure: days	8.94 (3.165)	11.85 (6.264)	10.59 (5.26)

Statistical Analysis 1 for Duration of Hospitalization

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.011
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Duration of Hospitalization

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority

	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.054
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Duration of Hospitalization

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.185
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Duration of Hospitalization

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.004
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

8. Secondary Outcome Measure:

Measure Title	Sequential Organ Function Assessment (SOFA) Score on Day 3

Measure Description	minimum 0 to maximum 24, higher scores mean worse outcomes Platelets, ×10³/μL ≥150 0 100-149+1 50-99+2 20-49+3 <20+4 Glasgow Coma Scale If on sedatives, estimate assumed GCS off sedatives 15 0 13-14+1 10-12+2 6-9+3 <6+4 Bilirubin, mg/dL (μmol/L) <1.2 (<20) 0 1.2–1.9 (20-32)+1 2.0–5.9 (33-101)+2 6.0–11.9 (102-204)+3 ≥12.0 (>204)+4 Mean arterial pressure OR administration of vasoactive agents required Listed doses are in units of mcg/kg/min No hypotension 0 MAP <70 mmHg+1 DOPamine ≤5 or DOBUTamine (any dose)+2 DOPamine >5, EPINEPHrine ≤0.1, or norEPINEPHrine ≤0.1+3 DOPamine >15, EPINEPHrine >0.1, or norEPINEPHrine >0.1+4 Creatinine, mg/dL (μmol/L) (or urine output) <1.2 (<110) 0 1.2–1.9 (110-170)+1 2.0–3.4 (171-299)+2 3.5–4.9 (300-440) or UOP <500 mL/day+3 ≥5.0 (>440) or UOP <200 mL/day+4
Time Frame	Day 3

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		53	106	106
Sequential Organ Function Assessment (SOFA) Score on Day 3	0	12 22.64%	1 0.94%	1 0.94%
	1	3 5.66%	8 7.55%	6 5.66%

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Measure Type: Count of Participants Unit of measure: participants	2	12 22.64%	12 11.32%	8 7.55%
	3	18 33.96%	24 22.64%	16 15.09%
	4	6 11.32%	40 37.74%	18 16.98%
	5	0 0%	4 3.77%	16 15.09%
	6	0 0%	5 4.72%	11 10.38%
	7	1 1.89%	4 3.77%	12 11.32%
	8	0 0%	4 3.77%	3 2.83%
	9	1 1.89%	1 0.94%	7 6.6%
	10	0 0%	0 0%	1 0.94%
	11	0 0%	0 0%	3 2.83%
	12	0 0%	2 1.89%	1 0.94%
	13	0 0%	1 0.94%	2 1.89%
	16	0 0%	0 0%	1 0.94%

Statistical Analysis 1 for Sequential Organ Function Assessment (SOFA) Score on Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Sequential Organ Function Assessment (SOFA) Score on Day 3

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority

	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Sequential Organ Function Assessment (SOFA) Score on Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Sequential Organ Function Assessment (SOFA) Score on Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

9. Secondary Outcome Measure:

Measure Title	COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 3
Measure Description	minimum 0 to maximum 10, higher scores mean worse outcomes
Time Frame	Day 3

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		52	106	106
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 3 Measure Type: Count of Participants Unit of measure: participants	WHO scale 3	0 0%	1 0.94%	0 0%
	WHO scale 4	25 48.08%	17 16.04%	17 16.04%
	WHO scale 5	20 38.46%	57 53.77%	58 54.72%
	WHO scale 6	7 13.46%	28 26.42%	22 20.75%
	WHO scale 8	0 0%	0 0%	5 4.72%
	WHO scale 9	0 0%	2 1.89%	4 3.77%
	WHO scale 10	0 0%	1 0.94%	0 0%

Statistical Analysis 1 for COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority

	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 3

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.758
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority

	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

10. Secondary Outcome Measure:

Measure Title	Aspartate Aminotransferase (AST) at Day 3
Measure Description	continuous level
Time Frame	day 3

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	53	106	106

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Aspartate Aminotransferase (AST) at Day 3 Mean (Standard Deviation) Unit of measure: Units/liter	48.53 (60.487)	48.67 (41.128)	43.93 (36.497)

Statistical Analysis 1 for Aspartate Aminotransferase (AST) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.412
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

11. Secondary Outcome Measure:

Measure Title	Ferritin at Day 3
Measure Description	continuous level
Time Frame	day 3

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies

	Description
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	53	106	106
Ferritin at Day 3 Mean (Standard Deviation) Unit of measure: micrograms per liter	393.04 (170.2)	427.25 (194.8)	1110 (6784.6)

Statistical Analysis 1 for Ferritin at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.106
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

12. Secondary Outcome Measure:

Measure Title	Lactate Dehydrogenase (LDH) at Day 3
Measure Description	continuous level

Time Frame	day 3

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	53	106	106
Lactate Dehydrogenase (LDH) at Day 3 Mean (Standard Deviation) Unit of measure: international units per liter	351.27 (258.57)	404.45 (214.92)	354.7 (204.2)

Statistical Analysis 1 for Lactate Dehydrogenase (LDH) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.01
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Lactate Dehydrogenase (LDH) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.06
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Lactate Dehydrogenase (LDH) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.156
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Lactate Dehydrogenase (LDH) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.003
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

13. Secondary Outcome Measure:

Measure Title	D-dimer at Day 3
Measure Description	continuous level
Time Frame	day 3

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	53	106	106
D-dimer at Day 3 Mean (Standard Deviation) Unit of measure: µg/mL	0.244 (0.2211)	0.23 (0.3321)	0.29 (0.3845)

Statistical Analysis 1 for D-dimer at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.219
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

14. Secondary Outcome Measure:

Measure Title	Alanine Aminotransferase (ALT) at Day 3
Measure Description	continuous level
Time Frame	day 3

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	53	106	106
Alanine Aminotransferase (ALT) at Day 3 Mean (Standard Deviation) Unit of measure: Units/liter	33.62 (34.535)	36.46 (32.585)	36.16 (49.86)

Statistical Analysis 1 for Alanine Aminotransferase (ALT) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.298
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

15. Secondary Outcome Measure:

Measure Title	Albumin at Day 3
Measure Description	continuous level
Time Frame	day 3

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies

	Description
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	53	106	106
Albumin at Day 3 Mean (Standard Deviation) Unit of measure: gm/dl	3.157 (0.3858)	2.947 (0.4507)	2.854 (0.504)

Statistical Analysis 1 for Albumin at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.015
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Albumin at Day 3

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority

	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.232
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Albumin at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.004
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Albumin at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.054
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

16. Secondary Outcome Measure:

Measure Title	Bilirubin at Day 3
Measure Description	continuous level
Time Frame	day 3

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	53	106	106
Bilirubin at Day 3 Mean (Standard Deviation) Unit of measure: milligram/deciliter	0.4793 (0.255)	0.6457 (0.654)	0.7053 (0.86)

Statistical Analysis 1 for Bilirubin at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.68
	Comments	[Not specified]

	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Bilirubin at Day 3

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.232
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Bilirubin at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.004
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Bilirubin at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.054
	Comments	[Not specified]

	Method	Kruskal-Wallis
	Comments	[Not specified]

17. Secondary Outcome Measure:

Measure Title	C-reactive Protein (CRP) at Day 3
Measure Description	continuous level
Time Frame	day 3

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	52	106	82
C-reactive Protein (CRP) at Day 3 Mean (Standard Deviation) Unit of measure: milligram/liter	33.89 (31.44)	52.61 (37.719)	64.1 (63.035)

Statistical Analysis 1 for C-reactive Protein (CRP) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]
Statistical Test of Hypothesis	P-Value	0.002
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for C-reactive Protein (CRP) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]
Statistical Test of Hypothesis	P-Value	0.557
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for C-reactive Protein (CRP) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]
Statistical Test of Hypothesis	P-Value	0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for C-reactive Protein (CRP) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.004
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

18. Secondary Outcome Measure:

Measure Title	Duration of Intensive Care Unit (ICU) Stay
Measure Description	duration of ICU stay
Time Frame	up to 60 days

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	53	106	106
Duration of Intensive Care Unit (ICU) Stay Mean (Standard Deviation) Unit of measure: days	1.45 (1.835)	7.6 (7.614)	6.69 (6.23)

Statistical Analysis 1 for Duration of Intensive Care Unit (ICU) Stay

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Duration of Intensive Care Unit (ICU) Stay

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.51
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Duration of Intensive Care Unit (ICU) Stay

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]

	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Duration of Intensive Care Unit (ICU) Stay

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

19. Secondary Outcome Measure:

Measure Title	C-reactive Protein (CRP) at Day 7
Measure Description	continuous level
Time Frame	day 7

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies

	Description
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	39	84	74
C-reactive Protein (CRP) at Day 7 Mean (Standard Deviation) Unit of measure: milligram/liter	14.06 (14.548)	47.43 (52.631)	65.73 (90.34)

Statistical Analysis 1 for C-reactive Protein (CRP) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for C-reactive Protein (CRP) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority

	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.891
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for C-reactive Protein (CRP) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for C-reactive Protein (CRP) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

20. Secondary Outcome Measure:

Measure Title	C-reactive Protein (CRP) at Day 14
Measure Description	continuous level
Time Frame	day 14

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	4	19	13
C-reactive Protein (CRP) at Day 14 Mean (Standard Deviation) Unit of measure: milligram/liter	7.5 (5.745)	37.05 (55.395)	39.31 (54.77)

Statistical Analysis 1 for C-reactive Protein (CRP) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.516
	Comments	[Not specified]

	Method	Kruskal-Wallis
	Comments	[Not specified]

21. Secondary Outcome Measure:

Measure Title	C-reactive Protein (CRP) at Day 28
Measure Description	continuous level
Time Frame	day 28

Analysis Population Description

patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	0	4	1
C-reactive Protein (CRP) at Day 28 Mean (Standard Deviation) Unit of measure: milligram/liter	---	39 (38.419)	96 (NA) [1]

[1] The number of participants is 1, so the Standard Deviation was not calculated

Statistical Analysis 1 for C-reactive Protein (CRP) at Day 28

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.264
	Comments	[Not specified]
	Method	Wilcoxon (Mann-Whitney)
	Comments	[Not specified]

22. Secondary Outcome Measure:

Measure Title	Sequential Organ Function Assessment (SOFA) Score on Day 7
Measure Description	minimum 0 to maximum 24, higher scores mean worse outcomes
Time Frame	day 7

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		39	84	74
Sequential Organ Function Assessment (SOFA) Score on Day 7 Measure Type: Count of Participants Unit of measure: participants	0	5 12.82%	1 1.19%	1 1.35%
	1	18 46.15%	4 4.76%	4 5.41%
	2	12 30.77%	10 11.9%	10 13.51%
	3	3 7.69%	13 15.48%	13 17.57%
	4	0 0%	28 33.33%	7 9.46%
	5	1 2.56%	7 8.33%	7 9.46%
	6	0 0%	6 7.14%	5 6.76%
	7	0 0%	2 2.38%	6 8.11%
	8	0 0%	1 1.19%	4 5.41%
	9	0 0%	2 2.38%	2 2.7%
	10	0 0%	4 4.76%	2 2.7%
	11	0 0%	3 3.57%	3 4.05%
	12	0 0%	0 0%	3 4.05%
	13	0 0%	1 1.19%	2 2.7%
	14	0 0%	1 1.19%	2 2.7%
	15	0 0%	1 1.19%	2 2.7%
	16	0 0%	0 0%	1 1.35%

Statistical Analysis 1 for Sequential Organ Function Assessment (SOFA) Score on Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis

	Comments	[Not specified]

Statistical Analysis 2 for Sequential Organ Function Assessment (SOFA) Score on Day 7

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.256
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Sequential Organ Function Assessment (SOFA) Score on Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Sequential Organ Function Assessment (SOFA) Score on Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis

	Comments	[Not specified]

23. Secondary Outcome Measure:

Measure Title	Sequential Organ Function Assessment Score (SOFA) on Day 14
Measure Description	minimum 0 to maximum 24, higher scores mean worse outcomes
Time Frame	day 14

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		4	19	16
Sequential Organ Function Assessment Score (SOFA) on Day 14 Measure Type: Count of Participants Unit of measure: participants	0	3 75%	1 5.26%	0 0%
	1	1 25%	1 5.26%	1 6.25%
	2	0 0%	1 5.26%	1 6.25%
	3	0 0%	2 10.53%	3 18.75%
	4	0 0%	4 21.05%	3 18.75%
	5	0 0%	4 21.05%	2 12.5%

		Casirivimab and Imdevimab	Remdesivir	Favipravir
	6	0 0%	0 0%	1 6.25%
	8	0 0%	2 10.53%	2 12.5%
	9	0 0%	1 5.26%	1 6.25%
	11	0 0%	2 10.53%	0 0%
	12	0 0%	0 0%	1 6.25%
	14	0 0%	1 5.26%	0 0%
	16	0 0%	0 0%	1 6.25%

Statistical Analysis 1 for Sequential Organ Function Assessment Score (SOFA) on Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.008
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Sequential Organ Function Assessment Score (SOFA) on Day 14

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.797
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Sequential Organ Function Assessment Score (SOFA) on Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.003
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Sequential Organ Function Assessment Score (SOFA) on Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.004
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

24. Secondary Outcome Measure:

Measure Title	Sequential Organ Function Assessment Score (SOFA) on Day 28
Measure Description	minimum 0 to maximum 24, higher scores mean worse outcomes
Time Frame	day 28

Analysis Population Description

patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		0	4	1
Sequential Organ Function Assessment Score (SOFA) on Day 28 Measure Type: Count of Participants Unit of measure: participants	0	---	1 25%	0 0%
	3	---	1 25%	0 0%
	12	---	1 25%	0 0%
	13	---	1 25%	0 0%
	17	---	0 0%	1 100%

Statistical Analysis 1 for Sequential Organ Function Assessment Score (SOFA) on Day 28

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.157
	Comments	[Not specified]
	Method	Wilcoxon (Mann-Whitney)

	Comments	[Not specified]

25. Secondary Outcome Measure:

Measure Title	COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 7
Measure Description	minimum 0 to maximum 10, higher scores mean worse outcomes
Time Frame	day 7

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		39	84	74
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 7 Measure Type: Count of Participants Unit of measure: participants	4	28 71.79%	20 23.81%	21 28.38%
	5	11 28.21%	28 33.33%	22 29.73%
	6	0 0%	26 30.95%	16 21.62%
	8	0 0%	3 3.57%	5 6.76%
	9	0 0%	7 8.33%	4 5.41%
	10	0 0%	0 0%	6 8.11%

Statistical Analysis 1 for COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]
Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 7

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]
Statistical Test of Hypothesis	P-Value	0.982
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]
Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

26. Secondary Outcome Measure:

Measure Title	COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 14
Measure Description	minimum 0 to maximum 10, higher scores mean worse outcomes
Time Frame	day 14

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		4	19	16
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 14 Measure Type: Count of Participants Unit of measure: participants	4	4 100%	2 10.53%	7 43.75%
	5	0 0%	8 42.11%	4 25%
	6	0 0%	3 15.79%	1 6.25%
	8	0 0%	3 15.79%	1 6.25%
	9	0 0%	3 15.79%	3 18.75%

Statistical Analysis 1 for COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.015
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 14

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.136
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.062
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.005
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

27. Secondary Outcome Measure:

Measure Title	COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 28
Measure Description	minimum 0 to maximum 10, higher scores mean worse outcomes
Time Frame	day 28

Analysis Population Description

patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		0	4	1
COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 28 Measure Type: Count of Participants Unit of measure: participants	5	---	2 50%	0 0%
	9	---	2 50%	0 0%
	10	---	0 0%	1 100%

Statistical Analysis 1 for COVID-19 World Health Organization (WHO) Disease Progression Scale at Day 28

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.136
	Comments	[Not specified]

	Method	Wilcoxon (Mann-Whitney)
	Comments	[Not specified]

28. Secondary Outcome Measure:

Measure Title	Aspartate Aminotransferase (AST) at Day 7
Measure Description	continuous level
Time Frame	day 7

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	39	84	74
Aspartate Aminotransferase (AST) at Day 7 Mean (Standard Deviation) Unit of measure: Units/liter	41.77 (32.465)	35.26 (20.089)	41.35 (39.78)

Statistical Analysis 1 for Aspartate Aminotransferase (AST) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.687
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

29. Secondary Outcome Measure:

Measure Title	Aspartate Aminotransferase (AST) at Day 14
Measure Description	continuous level
Time Frame	day 14

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	4	19	13
Aspartate Aminotransferase (AST) at Day 14 Mean (Standard Deviation) Unit of measure: Units/liter	26.75 (18.118)	22.79 (13.319)	30.19 (16.802)

Statistical Analysis 1 for Aspartate Aminotransferase (AST) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.278
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

30. Secondary Outcome Measure:

Measure Title	Aspartate Aminotransferase (AST) at Day 28
Measure Description	continuous level
Time Frame	day 28

Analysis Population Description

patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies

	Description
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	0	4	1
Aspartate Aminotransferase (AST) at Day 28 Mean (Standard Deviation) Unit of measure: Units/liter	---	31 (11.605)	27 (NA) [1]

[1] The number of participants is 1, so the Standard Deviation was not calculated

Statistical Analysis 1 for Aspartate Aminotransferase (AST) at Day 28

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.99
	Comments	[Not specified]
	Method	Wilcoxon (Mann-Whitney)
	Comments	[Not specified]

31. Secondary Outcome Measure:

Measure Title	Alanine Aminotransferase (ALT) at Day 7
Measure Description	Continuous level

Time Frame	day 7

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	39	84	74
Alanine Aminotransferase (ALT) at Day 7 Mean (Standard Deviation) Unit of measure: Units/liter	26 (18.604)	30.54 (23.062)	33.90 (33.58)

Statistical Analysis 1 for Alanine Aminotransferase (ALT) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.574
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

32. Secondary Outcome Measure:

Measure Title	Alanine Aminotransferase (ALT) at Day 14
Measure Description	Continuous level
Time Frame	day 14

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	4	19	13
Alanine Aminotransferase (ALT) at Day 14 Mean (Standard Deviation) Unit of measure: Units/liter	15.75 (4.856)	22.42 (15.788)	35.38 (17.55)

Statistical Analysis 1 for Alanine Aminotransferase (ALT) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]
Statistical Test of Hypothesis	P-Value	0.017
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Alanine Aminotransferase (ALT) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]
Statistical Test of Hypothesis	P-Value	0.017
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Alanine Aminotransferase (ALT) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]
Statistical Test of Hypothesis	P-Value	0.041
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Alanine Aminotransferase (ALT) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.616
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

33. Secondary Outcome Measure:

Measure Title	Alanine Aminotransferase (ALT) at Day 28
Measure Description	Continuous level
Time Frame	day 28

Analysis Population Description

patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	0	4	1
Alanine Aminotransferase (ALT) at Day 28 Mean (Standard Deviation) Unit of measure: Units/liter	---	71.75 (57)	39.5 (NA) [1]

[1] The number of participants is 1, so the Standard Deviation was not calculated

Statistical Analysis 1 for Alanine Aminotransferase (ALT) at Day 28

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.99
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

34. Secondary Outcome Measure:

Measure Title	Bilirubin at Day 7
Measure Description	Continuous level
Time Frame	day 7

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies

	Description
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	39	84	74
Bilirubin at Day 7 Mean (Standard Deviation) Unit of measure: milligram/deciliter	0.3717 (0.221)	0.6575 (0.699)	0.8886 (1.54)

Statistical Analysis 1 for Bilirubin at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Bilirubin at Day 7

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority

	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.208
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Bilirubin at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Bilirubin at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

35. Secondary Outcome Measure:

Measure Title	Bilirubin at Day 14
Measure Description	Continuous level
Time Frame	day 14

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	4	19	13
Bilirubin at Day 14 Mean (Standard Deviation) Unit of measure: milligram/deciliter	0.3625 (0.11)	0.494 (0.2229)	0.6888 (0.37)

Statistical Analysis 1 for Bilirubin at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.088
	Comments	[Not specified]

	Method	Kruskal-Wallis
	Comments	[Not specified]

36. Secondary Outcome Measure:

Measure Title	Bilirubin at Day 28
Measure Description	continuous level
Time Frame	day 28

Analysis Population Description

patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	0	4	1
Bilirubin at Day 28 Mean (Standard Deviation) Unit of measure: milligram/deciliter	---	0.41 (0.14376)	1.67 (NA) [1]

[1] The number of participants is 1, so the Standard Deviation was not calculated

Statistical Analysis 1 for Bilirubin at Day 28

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.157
	Comments	[Not specified]
	Method	Wilcoxon (Mann-Whitney)
	Comments	[Not specified]

37. Secondary Outcome Measure:

Measure Title	Albumin at Day 7
Measure Description	continuous level
Time Frame	day 7

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	39	84	74
Albumin at Day 7 Mean (Standard Deviation) Unit of measure: gm/dl	2.98 (0.4073)	2.77 (0.4837)	2.644 (0.489)

Statistical Analysis 1 for Albumin at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.006
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Albumin at Day 7

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.151
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Albumin at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]

	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Albumin at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.035
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

38. Secondary Outcome Measure:

Measure Title	Albumin at Day 14
Measure Description	continuous level
Time Frame	day 14

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies

	Description
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	4	19	13
Albumin at Day 14 Mean (Standard Deviation) Unit of measure: gm/dl	3.425 (0.2872)	2.82 (0.4184)	2.813 (0.368)

Statistical Analysis 1 for Albumin at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.037
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Albumin at Day 14

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority

	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.997
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Albumin at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.016
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Albumin at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.014
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

39. Secondary Outcome Measure:

Measure Title	Albumin at Day 28
Measure Description	continuous level
Time Frame	day 28

Analysis Population Description

patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	0	4	1
Albumin at Day 28 Mean (Standard Deviation) Unit of measure: gm/dl	---	2.575 (0.3304)	2.7 (NA) [1]

[1] The number of participants is 1, so the Standard Deviation was not calculated

Statistical Analysis 1 for Albumin at Day 28

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.48
	Comments	[Not specified]

	Method	Wilcoxon (Mann-Whitney)
	Comments	[Not specified]

40. Secondary Outcome Measure:

Measure Title	Platelets at Day 3
Measure Description	continuous level
Time Frame	day 3

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	53	106	106
Platelets at Day 3 Mean (Standard Deviation) Unit of measure: 10^3 cells/uL	271.64 (97.62)	253.425 (105)	226.35 (116.2)

Statistical Analysis 1 for Platelets at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.047
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Platelets at Day 3

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.04
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Platelets at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.036
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Platelets at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.67
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

41. Secondary Outcome Measure:

Measure Title	Platelets at Day 7
Measure Description	continuous level
Time Frame	day 7

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	39	84	74
Platelets at Day 7 Mean (Standard Deviation) Unit of measure: 10^3 cells/uL	268.829 (93.9)	243.514 (116.2)	212.76 (123.2)

Statistical Analysis 1 for Platelets at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.015
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Platelets at Day 7

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.027
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Platelets at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]

	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.008
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Platelets at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.38
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

42. Secondary Outcome Measure:

Measure Title	Platelets at Day 14
Measure Description	continuous level
Time Frame	day 14

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies

	Description
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	4	19	13
Platelets at Day 14 Mean (Standard Deviation) Unit of measure: 10^3 cells/uL	248 (136.48)	216.95 (126.3)	215.63 (126.3)

Statistical Analysis 1 for Platelets at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.814
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

43. Secondary Outcome Measure:

Measure Title	Platelets at Day 28
Measure Description	continuous level

Time Frame	day 28

Analysis Population Description

patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	0	4	1
Platelets at Day 28 Mean (Standard Deviation) Unit of measure: 10^3 cells/uL	---	246.75 (113)	15 (NA) [1]

[1] Standard Deviation not calculable as only 1 participant was analyzed

Statistical Analysis 1 for Platelets at Day 28

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.157
	Comments	[Not specified]
	Method	Wilcoxon (Mann-Whitney)
	Comments	[Not specified]

44. Secondary Outcome Measure:

Measure Title	Serum Creatinine (S.Cr) at Day 3
Measure Description	continuous level
Time Frame	day 3

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	53	106	106
Serum Creatinine (S.Cr) at Day 3 Mean (Standard Deviation) Unit of measure: milligram/deciliter	1.0769 (0.941)	0.9546 (0.865)	1.6568 (1.776)

Statistical Analysis 1 for Serum Creatinine (S.Cr) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]
Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Serum Creatinine (S.Cr) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]
Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Serum Creatinine (S.Cr) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]
Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Serum Creatinine (S.Cr) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.971
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

45. Secondary Outcome Measure:

Measure Title	Serum Creatinine (S.Cr) at Day 7
Measure Description	continuous level
Time Frame	day 7

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	39	84	74
Serum Creatinine (S.Cr) at Day 7 Mean (Standard Deviation) Unit of measure: milligram/deciliter	0.9674 (0.752)	0.9952 (0.987)	1.6541 (1.9)

Statistical Analysis 1 for Serum Creatinine (S.Cr) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Serum Creatinine (S.Cr) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

46. Secondary Outcome Measure:

Measure Title	Serum Creatinine (S.Cr) at Day 14

Measure Description	continuous level
Time Frame	day 14

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	4	19	13
Serum Creatinine (S.Cr) at Day 14 Mean (Standard Deviation) Unit of measure: milligram/deciliter	0.775 (0.221)	0.6316 (0.152)	1.45 (1.7753)

Statistical Analysis 1 for Serum Creatinine (S.Cr) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.007
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Serum Creatinine (S.Cr) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.017
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Serum Creatinine (S.Cr) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.452
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Serum Creatinine (S.Cr) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.237
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

47. Secondary Outcome Measure:

Measure Title	Serum Creatinine (S.Cr) at Day 28
Measure Description	continuous level
Time Frame	day 28

Analysis Population Description

patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	0	4	1
Serum Creatinine (S.Cr) at Day 28 Mean (Standard Deviation) Unit of measure: milligram/deciliter	---	0.525 (0.1708)	1.2 (NA) [1]

[1] Standard Deviation not calculable as only 1 participant was analyzed

Statistical Analysis 1 for Serum Creatinine (S.Cr) at Day 28

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.157
	Comments	[Not specified]
	Method	Wilcoxon (Mann-Whitney)
	Comments	[Not specified]

48. Secondary Outcome Measure:

Measure Title	D-dimer at Day 7
Measure Description	continuous level
Time Frame	day 7

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	39	84	74
D-dimer at Day 7 Mean (Standard Deviation) Unit of measure: µg/mL	0.109 (0.1483)	0.319 (0.5017)	0.425 (0.5678)

Statistical Analysis 1 for D-dimer at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.015
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for D-dimer at Day 7

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.223
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for D-dimer at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.004
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for D-dimer at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.05
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

49. Secondary Outcome Measure:

Measure Title	D-dimer at Day 14
Measure Description	continuous level
Time Frame	day 14

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	4	19	13
D-dimer at Day 14 Mean (Standard Deviation) Unit of measure: µg/mL	0.05 (0.1)	0.41 (0.5999)	0.313 (0.461)

Statistical Analysis 1 for D-dimer at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.423
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

50. Secondary Outcome Measure:

Measure Title	D-dimer at Day 28
Measure Description	continuous level
Time Frame	day 28

Analysis Population Description

patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	0	4	1
D-dimer at Day 28 Mean (Standard Deviation) Unit of measure: µg/mL	---	0.4 (0.8)	0.4 (NA) [1]

[1] Standard Deviation not calculable as only 1 participant was analyzed

Statistical Analysis 1 for D-dimer at Day 28

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]

	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.429
	Comments	[Not specified]
	Method	Wilcoxon (Mann-Whitney)
	Comments	[Not specified]

51. Secondary Outcome Measure:

Measure Title	Creatine Kinase (Ck) at Day 3
Measure Description	continuous level
Time Frame	day 3

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	53	106	106

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Creatine Kinase (Ck) at Day 3 Mean (Standard Deviation) Unit of measure: Units/liter	142.2 (135.12)	197.94 (342.1)	181.45 (166)

Statistical Analysis 1 for Creatine Kinase (Ck) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.089
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

52. Secondary Outcome Measure:

Measure Title	Creatine Kinase (Ck) at Day 7
Measure Description	continuous level
Time Frame	day 7

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies

	Description
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	39	84	74
Creatine Kinase (Ck) at Day 7 Mean (Standard Deviation) Unit of measure: Units/liter	126.743 (112)	211.9 (420.23)	175.99 (155)

Statistical Analysis 1 for Creatine Kinase (Ck) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.222
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

53. Secondary Outcome Measure:

Measure Title	Creatine Kinase (Ck) at Day 14
Measure Description	continuous level

Time Frame	day 14

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	4	19	13
Creatine Kinase (Ck) at Day 14 Mean (Standard Deviation) Unit of measure: Units/liter	49.5 (30.116)	122.89 (93.259)	142.75 (176)

Statistical Analysis 1 for Creatine Kinase (Ck) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.252
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

54. Secondary Outcome Measure:

Measure Title	Creatine Kinase (Ck) at Day 28
Measure Description	continuous level
Time Frame	day 28

Analysis Population Description

patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	0	4	1
Creatine Kinase (Ck) at Day 28 Mean (Standard Deviation) Unit of measure: Units/liter	---	119.22 (88.21)	134.25 (NA) [1]

[1] Standard Deviation not calculable as only 1 participant was analyzed

Statistical Analysis 1 for Creatine Kinase (Ck) at Day 28

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.157
	Comments	[Not specified]
	Method	Wilcoxon (Mann-Whitney)
	Comments	[Not specified]

55. Secondary Outcome Measure:

Measure Title	Lactate Dehydrogenase (LDH) at Day 7
Measure Description	continuous level
Time Frame	day 7

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	39	84	74
Lactate Dehydrogenase (LDH) at Day 7 Mean (Standard Deviation) Unit of measure: international units per liter	271.4 (165.99)	371.37 (196.2)	349.68 (201)

Statistical Analysis 1 for Lactate Dehydrogenase (LDH) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.007
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Lactate Dehydrogenase (LDH) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.382
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Lactate Dehydrogenase (LDH) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.017
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Lactate Dehydrogenase (LDH) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.002
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

56. Secondary Outcome Measure:

Measure Title	Lactate Dehydrogenase (LDH) at Day 14
Measure Description	continuous level
Time Frame	day 14

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	4	19	13
Lactate Dehydrogenase (LDH) at Day 14 Mean (Standard Deviation) Unit of measure: international units per liter	379.75 (313.9)	360.89 (244.8)	306.88 (266)

Statistical Analysis 1 for Lactate Dehydrogenase (LDH) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.457
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

57. Secondary Outcome Measure:

Measure Title	Lactate Dehydrogenase (LDH) at Day 28
Measure Description	continuous level
Time Frame	day 28

Analysis Population Description

patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	0	4	1
Lactate Dehydrogenase (LDH) at Day 28 Mean (Standard Deviation) Unit of measure: international units per liter	---	314.5 (108.99)	270 (NA) [1]

[1] Standard Deviation not calculable as only 1 participant was analyzed

Statistical Analysis 1 for Lactate Dehydrogenase (LDH) at Day 28

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]

	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.48
	Comments	[Not specified]
	Method	Wilcoxon (Mann-Whitney)
	Comments	[Not specified]

58. Secondary Outcome Measure:

Measure Title	Ferritin at Day 7
Measure Description	continuous level
Time Frame	day 7

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	39	84	74

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Ferritin at Day 7 Mean (Standard Deviation) Unit of measure: micrograms per liter	368.42 (167.8)	450.37 (247.6)	1433 (8174)

Statistical Analysis 1 for Ferritin at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.01
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Ferritin at Day 7

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.605
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Ferritin at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority

	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.003
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Ferritin at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.01
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

59. Secondary Outcome Measure:

Measure Title	Ferritin at Day 14
Measure Description	continuous level
Time Frame	day 14

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies

	Description
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	4	19	13
Ferritin at Day 14 Mean (Standard Deviation) Unit of measure: micrograms per liter	398.5 (131.43)	637.37 (436)	519.88 (431)

Statistical Analysis 1 for Ferritin at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.293
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

60. Secondary Outcome Measure:

Measure Title	Ferritin at Day 28
Measure Description	continuous level

Time Frame	day 28

Analysis Population Description

patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	0	4	1
Ferritin at Day 28 Mean (Standard Deviation) Unit of measure: micrograms per liter	---	1355 (896.3)	410 (NA) [1]

[1] Standard Deviation not calculable as only 1 participant was analyzed

Statistical Analysis 1 for Ferritin at Day 28

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.157
	Comments	[Not specified]
	Method	Wilcoxon (Mann-Whitney)
	Comments	[Not specified]

61. Secondary Outcome Measure:

Measure Title	Incidence of Acute Kidney Injury (AKI)
Measure Description	Incidence of acute kidney injury (AKI)
Time Frame	up to 60 days

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		53	106	106
Incidence of Acute Kidney Injury (AKI)	yes	1 1.89%	4 3.77%	7 6.6%
	no	52 98.11%	102 96.23%	99 93.4%

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Measure Type: Count of Participants Unit of measure: participants				

Statistical Analysis 1 for Incidence of Acute Kidney Injury (AKI)

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.36
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

62. Secondary Outcome Measure:

Measure Title	Incidence of Acute Liver Damage (ALD)
Measure Description	Incidence of acute liver damage (ALD)
Time Frame	up to 60 days

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug

	Description
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		53	106	106
Incidence of Acute Liver Damage (ALD) Measure Type: Count of Participants Unit of measure: participants	yes	1 1.89%	6 5.66%	3 2.83%
	no	52 98.11%	100 94.34%	103 97.17%

Statistical Analysis 1 for Incidence of Acute Liver Damage (ALD)

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.404
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

63. Secondary Outcome Measure:

Measure Title	Day of Death
Measure Description	day of death
Time Frame	up to 60 days

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	53	106	106
Day of Death Mean (Standard Deviation) Unit of measure: day	0.19 (1.061)	12.57 (6.22)	10.13 (6.530)

Statistical Analysis 1 for Day of Death

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Day of Death

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.234
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Day of Death

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Day of Death

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

64. Secondary Outcome Measure:

Measure Title	Mortality at Discharge
Measure Description	mortality at discharge
Time Frame	up to 60 days

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		53	106	106
Mortality at Discharge Measure Type: Count of Participants Unit of measure: participants	dead	1 1.89%	33 31.13%	41 38.68%
	alive	52 98.11%	73 68.87%	65 61.32%

Statistical Analysis 1 for Mortality at Discharge

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority

	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Mortality at Discharge

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.223
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Mortality at Discharge

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Mortality at Discharge

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority

	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

65. Other Pre-specified Outcome Measure:

Measure Title	Glasgow Coma Score (GCS) at Day 3
Measure Description	minimum 0 to maximum 15, higher scores mean better outcomes
Time Frame	day 3

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		53	106	106
Glasgow Coma Score (GCS) at Day 3	3	0 0%	3 2.83%	6 5.66%
	4	0 0%	1 0.94%	0 0%

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Measure Type: Count of Participants Unit of measure: participants	6	0 0%	1 0.94%	0 0%
	7	0 0%	0 0%	1 0.94%
	8	0 0%	0 0%	1 0.94%
	9	0 0%	0 0%	1 0.94%
	10	0 0%	2 1.89%	10 9.43%
	12	0 0%	0 0%	1 0.94%
	13	1 1.89%	0 0%	3 2.83%
	14	1 1.89%	5 4.72%	6 5.66%
	15	51 96.23%	94 88.68%	77 72.64%

Statistical Analysis 1 for Glasgow Coma Score (GCS) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Glasgow Coma Score (GCS) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.002
	Comments	[Not specified]
	Method	Kruskal-Wallis

	Comments	[Not specified]

Statistical Analysis 3 for Glasgow Coma Score (GCS) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Glasgow Coma Score (GCS) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.213
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

66. Other Pre-specified Outcome Measure:

Measure Title	Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 3
Measure Description	continuous level
Time Frame	day 3

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	53	106	106
Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 3 Mean (Standard Deviation) Unit of measure: Ratio	298.57 (211.3)	154.14 (138.9)	166.96 (130)

Statistical Analysis 1 for Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.478
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 3

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

67. Other Pre-specified Outcome Measure:

Measure Title	Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 7
Measure Description	continuous level
Time Frame	day 7

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	39	84	74
Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 7 Mean (Standard Deviation) Unit of measure: Ratio	320.62 (93.64)	163.55 (172.6)	178.59 (138)

Statistical Analysis 1 for Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]

	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.413
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]

	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

68. Other Pre-specified Outcome Measure:

Measure Title	Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 14
Measure Description	continuous level
Time Frame	day 14

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	4	19	13

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 14 Mean (Standard Deviation) Unit of measure: Ratio	389.75 (51.93)	154.67 (174)	165.2 (98.87)

Statistical Analysis 1 for Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.005
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.155
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority

	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.022
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

69. Other Pre-specified Outcome Measure:

Measure Title	Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 28
Measure Description	continuous level
Time Frame	day 28

Analysis Population Description

patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies

	Description
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

	Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed	0	4	1
Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 28 Mean (Standard Deviation) Unit of measure: Ratio	---	172.75 (181)	53 (NA) [1]

[1] Standard Deviation not calculable as only 1 participant was analyzed

Statistical Analysis 1 for Arterial Oxygen Pressure / Fraction Inspired of Oxygen (PaO2/FiO2) at Day 28

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.48
	Comments	[Not specified]
	Method	Wilcoxon (Mann-Whitney)
	Comments	[Not specified]

70. Other Pre-specified Outcome Measure:

Measure Title	Glasgow Coma Score (GCS) at Day 7

Measure Description	minimum 0 to maximum 15, higher scores mean better outcomes
Time Frame	day 7

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		39	84	74
Glasgow Coma Score (GCS) at Day 7 Measure Type: Count of Participants Unit of measure: participants	3	0 0%	10 11.9%	13 17.57%
	6	0 0%	1 1.19%	1 1.35%
	7	0 0%	0 0%	1 1.35%
	9	0 0%	0 0%	1 1.35%
	10	0 0%	3 3.57%	11 14.86%
	12	0 0%	0 0%	1 1.35%
	13	0 0%	1 1.19%	1 1.35%
	14	0 0%	3 3.57%	3 4.05%
	15	39 100%	66 78.57%	42 56.76%

Statistical Analysis 1 for Glasgow Coma Score (GCS) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 2 for Glasgow Coma Score (GCS) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.003
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 3 for Glasgow Coma Score (GCS) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	<0.001
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

Statistical Analysis 4 for Glasgow Coma Score (GCS) at Day 7

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.011
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

71. Other Pre-specified Outcome Measure:

Measure Title	Glasgow Coma Score (GCS) at Day 14
Measure Description	minimum 0 to maximum 15, higher scores mean better outcomes
Time Frame	day 14

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		4	19	13
Glasgow Coma Score (GCS) at Day 14 Measure Type: Count of Participants Unit of measure: participants	3	0 0%	6 31.58%	4 30.77%
	10	0 0%	0 0%	0 0%
	13	0 0%	1 5.26%	0 0%
	14	0 0%	1 5.26%	2 15.38%
	15	4 100%	11 57.89%	7 53.85%

Statistical Analysis 1 for Glasgow Coma Score (GCS) at Day 14

Statistical Analysis Overview	Comparison Group Selection	Casirivimab and Imdevimab, Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.189
	Comments	[Not specified]
	Method	Kruskal-Wallis
	Comments	[Not specified]

72. Other Pre-specified Outcome Measure:

Measure Title	Glasgow Coma Score (GCS) at Day 28
Measure Description	minimum 0 to maximum 15, higher scores mean better outcomes
Time Frame	day 28

Analysis Population Description

patients who received casirivimab and imdevimab, not stayed at hospital until day of 28

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

Measured Values

		Casirivimab and Imdevimab	Remdesivir	Favipravir
Overall Number of Participants Analyzed		0	4	1
Glasgow Coma Score (GCS) at Day 28 Measure Type: Count of Participants Unit of measure: participants	3	---	2 50%	1 100%
	15	---	2 50%	NA [1]

[1] Standard Deviation not calculable as only 1 participant was analyzed

Statistical Analysis 1 for Glasgow Coma Score (GCS) at Day 28

Statistical Analysis Overview	Comparison Group Selection	Remdesivir, Favipravir
	Comments	[Not specified]
	Type of Statistical Test	Superiority
	Comments	[Not specified]

Statistical Test of Hypothesis	P-Value	0.414
	Comments	[Not specified]
	Method	Wilcoxon (Mann-Whitney)

	Comments	[Not specified]

Reported Adverse Events

Time Frame	up to 60 days
Adverse Event Reporting Description	[Not specified]

Reporting Groups

	Description
Casirivimab and Imdevimab	casirivimab and imdevimab, vials 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes. Casirivimab and Imdevimab Drug Combination: antiviral Monoclonal Antibodies
Remdesivir	Remdesivir, vials Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes Remdesivir: antiviral drug
Favipravir	Favipravir, tablets Day 1 (loading dose): 1600 mg (8 tablets) orally or in Ryle tube / 12 hours day 2-10 (maintenance dose): 800 mg (4 tablets) orally or in Ryle tube / 12 hours Favipiravir: antiviral drug

All-Cause Mortality

	Casirivimab and Imdevimab	Remdesivir	Favipravir
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total All-Cause Mortality	1/53 (1.89%)	34/106 (32.08%)	43/106 (40.57%)

Serious Adverse Events

	Casirivimab and Imdevimab	Remdesivir	Favipravir
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total	0/53 (0%)	0/106 (0%)	0/106 (0%)

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 0%

	Casirivimab and Imdevimab	Remdesivir	Favipravir
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total	0/53 (0%)	0/106 (0%)	0/106 (0%)

Limitations and Caveats

1. applicable only on hospitalized COVID-19 patients (not include outpatients),
2. non-randomization of antiviral drugs among included patients,
3. non-blinding of interventions to investigators

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:

Name/Official Title: Dr. Ahmed Hosny
Organization: Mansoura University Hospital
Phone: +2001554658010 Ext: +200115584
Email: ahmedony26@gmail.com